Genital Herpes Simplex Infections in Patients With the Acquired Immunodeficiency Syndrome

Betty J. McGrath, Cheryl L Newman

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

On August 14, 1987, the Centers for Disease Control revised the surveillance case definition for the acquired immunodeficiency syndrome (AIDS) to include several indicator diseases. The addition of herpes simplex virus (HSV) infections to the definition reemphasized the increasing frequency of severe HSV infections in patients also infected with the human immunodeficiency virus (HIV). These infections in patients with AIDS are associated with considerable morbidity similar to reports of HSV in other immunocompromised populations. Their spectrum can include persistent or recurrent genital disease, severe visceral involvement, and disseminated infection. Patients with AIDS also are at increased risk of drug toxicities when receiving treatment for HSV infections in addition to antiretroviral therapy. Acyclovir, a selective and specific inhibitor of HSV replication, has been the mainstay of safe and effective treatment for HSV for more than a decade. However, reports of acyclovir‐resistant strains of HSV in patients with AIDS have been steadily increasing since 1989. Although foscarnet has been successful in treating acyclovir‐resistant strains, foscarnet‐resistant strains have also been isolated. The search to find novel approaches for the treatment and suppression of HSV in patients with AIDS has become an added challenge in the management of this devastating disease. 1994 Pharmacotherapy Publications Inc.

Original languageEnglish (US)
Pages (from-to)529-542
Number of pages14
JournalPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume14
Issue number5
DOIs
StatePublished - Jan 1 1994

Fingerprint

Herpes Genitalis
Simplexvirus
Acquired Immunodeficiency Syndrome
Infection
Virus Diseases
Foscarnet
Acyclovir
Therapeutics
Centers for Disease Control and Prevention (U.S.)
Virus Replication
Disease Management
Drug-Related Side Effects and Adverse Reactions
Publications
HIV
Morbidity
Drug Therapy

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Genital Herpes Simplex Infections in Patients With the Acquired Immunodeficiency Syndrome. / McGrath, Betty J.; Newman, Cheryl L.

In: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Vol. 14, No. 5, 01.01.1994, p. 529-542.

Research output: Contribution to journalReview article

@article{e1a1ebfc4408427ea1b5fa6a933a6260,
title = "Genital Herpes Simplex Infections in Patients With the Acquired Immunodeficiency Syndrome",
abstract = "On August 14, 1987, the Centers for Disease Control revised the surveillance case definition for the acquired immunodeficiency syndrome (AIDS) to include several indicator diseases. The addition of herpes simplex virus (HSV) infections to the definition reemphasized the increasing frequency of severe HSV infections in patients also infected with the human immunodeficiency virus (HIV). These infections in patients with AIDS are associated with considerable morbidity similar to reports of HSV in other immunocompromised populations. Their spectrum can include persistent or recurrent genital disease, severe visceral involvement, and disseminated infection. Patients with AIDS also are at increased risk of drug toxicities when receiving treatment for HSV infections in addition to antiretroviral therapy. Acyclovir, a selective and specific inhibitor of HSV replication, has been the mainstay of safe and effective treatment for HSV for more than a decade. However, reports of acyclovir‐resistant strains of HSV in patients with AIDS have been steadily increasing since 1989. Although foscarnet has been successful in treating acyclovir‐resistant strains, foscarnet‐resistant strains have also been isolated. The search to find novel approaches for the treatment and suppression of HSV in patients with AIDS has become an added challenge in the management of this devastating disease. 1994 Pharmacotherapy Publications Inc.",
author = "McGrath, {Betty J.} and Newman, {Cheryl L}",
year = "1994",
month = "1",
day = "1",
doi = "10.1002/j.1875-9114.1994.tb02850.x",
language = "English (US)",
volume = "14",
pages = "529--542",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Genital Herpes Simplex Infections in Patients With the Acquired Immunodeficiency Syndrome

AU - McGrath, Betty J.

AU - Newman, Cheryl L

PY - 1994/1/1

Y1 - 1994/1/1

N2 - On August 14, 1987, the Centers for Disease Control revised the surveillance case definition for the acquired immunodeficiency syndrome (AIDS) to include several indicator diseases. The addition of herpes simplex virus (HSV) infections to the definition reemphasized the increasing frequency of severe HSV infections in patients also infected with the human immunodeficiency virus (HIV). These infections in patients with AIDS are associated with considerable morbidity similar to reports of HSV in other immunocompromised populations. Their spectrum can include persistent or recurrent genital disease, severe visceral involvement, and disseminated infection. Patients with AIDS also are at increased risk of drug toxicities when receiving treatment for HSV infections in addition to antiretroviral therapy. Acyclovir, a selective and specific inhibitor of HSV replication, has been the mainstay of safe and effective treatment for HSV for more than a decade. However, reports of acyclovir‐resistant strains of HSV in patients with AIDS have been steadily increasing since 1989. Although foscarnet has been successful in treating acyclovir‐resistant strains, foscarnet‐resistant strains have also been isolated. The search to find novel approaches for the treatment and suppression of HSV in patients with AIDS has become an added challenge in the management of this devastating disease. 1994 Pharmacotherapy Publications Inc.

AB - On August 14, 1987, the Centers for Disease Control revised the surveillance case definition for the acquired immunodeficiency syndrome (AIDS) to include several indicator diseases. The addition of herpes simplex virus (HSV) infections to the definition reemphasized the increasing frequency of severe HSV infections in patients also infected with the human immunodeficiency virus (HIV). These infections in patients with AIDS are associated with considerable morbidity similar to reports of HSV in other immunocompromised populations. Their spectrum can include persistent or recurrent genital disease, severe visceral involvement, and disseminated infection. Patients with AIDS also are at increased risk of drug toxicities when receiving treatment for HSV infections in addition to antiretroviral therapy. Acyclovir, a selective and specific inhibitor of HSV replication, has been the mainstay of safe and effective treatment for HSV for more than a decade. However, reports of acyclovir‐resistant strains of HSV in patients with AIDS have been steadily increasing since 1989. Although foscarnet has been successful in treating acyclovir‐resistant strains, foscarnet‐resistant strains have also been isolated. The search to find novel approaches for the treatment and suppression of HSV in patients with AIDS has become an added challenge in the management of this devastating disease. 1994 Pharmacotherapy Publications Inc.

UR - http://www.scopus.com/inward/record.url?scp=0028109021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028109021&partnerID=8YFLogxK

U2 - 10.1002/j.1875-9114.1994.tb02850.x

DO - 10.1002/j.1875-9114.1994.tb02850.x

M3 - Review article

C2 - 7997387

AN - SCOPUS:0028109021

VL - 14

SP - 529

EP - 542

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5

ER -